Mike Heier
About Mike Heier
Mike Heier is the Senior Manager Program Management at Boston Scientific, leading the Interventional Oncology New Therapy Accelerator program and possessing extensive expertise in Med Tech industry standards and quality assurance.
Title
Mike Heier holds the position of Senior Manager Program Management at Boston Scientific.
Current Role at Boston Scientific
Since 2023, Mike Heier has been serving as the Senior Manager Program Management at Boston Scientific in Maple Grove, Minnesota. In this hybrid role, he leads key initiatives and programs aimed at advancing innovative medical technologies.
Previous Roles at Boston Scientific
Prior to his current role, Mike Heier held a number of positions at Boston Scientific. From 2021 to 2023, he worked as a Program Manager. From 2019 to 2021, he served as a Quality Assurance Manager. Additionally, he was a Design Quality Engineer from 2005 to 2011. Throughout these roles, he contributed significantly to various quality assurance and program management aspects of the company.
Previous Experience
Before rejoining Boston Scientific, Mike Heier worked at Greatbatch Medical as a Senior Quality Engineer from 2013 to 2014 in the Greater Minneapolis-St. Paul Area. He also served as a Certified Quality Engineer at Bio-Rad Laboratories from 2011 to 2013 in Woodinville, WA. These roles helped him gain expertise in quality engineering and assurance.
Education and Expertise
Mike Heier studied Chemical Engineering at the University of Minnesota, earning his B.A. degree in 2005. He has substantial expertise in early technology development, Mergers & Acquisitions within the Med Tech industry, as well as ISO standards and FDA regulations. He serves as a Subject Matter Expert in Statistics and Validation and Verification testing.
Program Leadership at Boston Scientific
At Boston Scientific, Mike Heier leads the Interventional Oncology New Therapy Accelerator program. This initiative is focused on developing new transformational therapies in the field of interventional oncology, reflecting his commitment to advancing medical technology.